Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Oligoprogressive × Immune Checkpoint Inhibitors × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Renal Cell 2 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oligoprogressive 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Liver Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Bites and Stings 1

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1 DEAE-Dextran 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05846659 2024-12-09

Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡